Top-5 rankings: the beat sheet
No narrator. An editor ranks five products and ours is first. Written from the teardowns of the ranking pages David kept. It is what the CS-P1 upgrade is measured against.
What this family does
The kept rankings sell the rules before they sell the winner. The first fifth of the page teaches the reader how to judge a bottle. The winner then arrives as the result of a test she has already agreed to. Four rival cards let her finish her comparison shopping without leaving the page.
On the strongest pages the winner's card sits 15% to 20% down, and the first button is at the foot of that card, about a third of the way down.
The order
| # | Beat | Share | What it does to the reader | Ours on CS-P1 |
|---|---|---|---|---|
| 1 | Title and subhead | 2% | She knows it is a ranking, and what it was ranked on | has it: five softgels, three tests, the organs named |
| 2 | Who ranked | 1% | A named person stands behind the list | has it: the editor's byline |
| 3 | Her own cabinet | 4% | She sees the bottles she already takes, and that she could not say what they did | partly: the intro states it as a fact. It is not acted out |
| 4 | The turn | 3% | The idea is cleared and the bottle is blamed, so buying again is reasonable | partly: the potency fact sits in the method box, without the turn |
| 5 | The standards | 8% | Each test with its reason | has it: the method box, five things |
| 6 | The rule | 2% | Qualify on the standards, then rank on named factors. Rivals can pass and still place lower | lacks it |
| 7 | The winner, first | 18% | Every later card is read against it. Its pros repeat the standards in the same order | has it |
| 8 | Rival cards | 45% | Praise first. Marked down only on facts she can check. One sentence says why it ranks there. The card ends on who should still buy it | partly: fair and checked, but the order does not follow the scores, and no card says who it suits |
| 9 | Where the facts came from | 1% | A dated source under each card | lacks it |
| 10 | The short version | 4% | The standards again, as ticks, for the reader who skipped the cards | lacks it |
| 11 | The rule of thumb | 1% | One sentence she can use on any bottle | lacks it |
| 12 | The ask | 5% | The guarantee is in the button's wording | has it |
Take
- Teach the standards before the first product is named.
- Winner first. The reader compares down from it.
- Rivals get their due before they are marked down, and only on facts a reader can check on the rival's own page.
- A rival's rank matches its scores.
- A dated source line under every card, ours included.
- A recap and a rule of thumb after the last rival.
Leave
- The invented tester and the counts of products "tried".
- Letter grades with no method.
- Scores from a customer survey that does not exist. Our proof slot holds the clinical studies until our own panel has run.
- The carrier-oil standard. It is banned for us.
- A rival below the 12 mg serving on the list. Ours compares the same kind of product only.
What the three headline variants test
The store runs one ranking template under several titles. The general title names the nutrient. The kidney title names the organ first and keeps the nutrient for the introduction. The second layout adds a method box, a rule above the cards and one line of reasoning under each rival's grade, and it reads as the most defensible of the three.
The pages David kept
| Page | Type | Narrator | House chief | Product named at | Big idea |
|---|---|---|---|---|---|
| Top 5 Fatty Liver Supplements of 2026 – Clarity MD claritymd.co | F4 | editor | 7/10 | 16% | Liver supplements fail on amount and form, not on the idea: judge them on three standards and only one product passes all three. |
| Top 5 Astaxanthin Supplements of 2026 v2 – Clarity MD claritymd.co · twin of claritymd--top-5-astaxanthin-supplements-of-2026-vstd-282 | F4 | editor | 7/10 | 19% | Several products meet the three research-backed standards; of fifteen tried, one offers the best package beyond them. |
| Top 5 Astaxanthin Supplements of 2026 – Clarity MD claritymd.co | F4 | editor | 6/10 | 14% | The ingredient is sound; most bottles fail on dose, source or format, and a tester who tried the popular ones found a single product that passes all three at the lowest stated price. |
| We Ranked the 3 Most-Hyped Longevity Antioxidants of 2026 – Rovina tryrovina.com · twin of rovina--best-astaxanthin-2026 | F4 | researcher | 7.5/10 | 44% | Famous antioxidants guard only half the cell; one molecule covers both halves and gets to the cell's power plants. |
| Top 5 Astaxanthin Liver Supplements of 2026 – Clarity MD claritymd.co | F4 | editor | 5/10 | 21% | One focused antioxidant taken every day protects an overworked liver better than a multi-herb cleanse. |
| Top 5 Astaxanthin Supplements of 2026 – Rovina tryrovina.com | F4 | editor | 5/10 | 15% | Astaxanthin works and most bottles fail to deliver it; a short formulation test (dose, source, delivery) picks out the one that does. |
| 2026 Astaxanthin Review – Rovina tryrovina.com | F4 | doctor | 7/10 | 44% | The bottle you tried did nothing because it failed one of three tests that a fat-soluble molecule has to pass; one product passes all three. |
The numbers under the sheet
Across this family's teardowns: where each beat first appears, how much of the page it takes, and the levers it pulls.
| First at | Beat | Pages | Share of words | Levers |
|---|---|---|---|---|
| 0.2% | disclosure | 7/7 | 5.9% | nonecandorcontrastborrowed-authority |
| 0.8% | hook-headline | 7/7 | 0.7% | specificitycuriosity-gapearned-authoritycontrast |
| 1.8% | deck | 7/7 | 1.7% | loss-aversionopen-loopcontrastborrowed-authority |
| 2.8% | authority-stamp | 7/7 | 0.9% | earned-authorityeaseborrowed-authorityspecificity |
| 3.4% | page-furniture | 5/7 | 0.8% | easenoneborrowed-authority |
| 4.7% | image | 7/7 | 0.0% | easenoneanchoringborrowed-authority |
| 6.2% | failed-solutions | 5/7 | 1.5% | mirroringidentificationcuriosity-gapconsensus |
| 8.8% | turning-point | 5/7 | 4.9% | earned-authorityopen-loopspecificitycandor |
| 9.1% | symptom-mirror | 4/7 | 5.4% | mirroringidentificationfear-of-declinehope |
| 9.2% | villain-reveal | 6/7 | 1.4% | common-enemyvindicationreason-whycontrast |
| 10.1% | ranking-criteria | 7/7 | 6.5% | specificityreason-whycontrastopen-loop |
| 15.7% | proof-social | 5/7 | 4.0% | social-proofspecificityconsensusrisk-reversal |
| 20.7% | ranked-entry | 7/7 | 49.7% | contrastcandorspecificityreason-why |
| 33.2% | mechanism | 4/7 | 7.3% | new-mechanismreason-whycontrastloop-closed |
| 33.9% | cta | 7/7 | 1.5% | easecommitmentrisk-reversalcuriosity-gap |
| 35.2% | proof-study | 4/7 | 3.2% | borrowed-authorityconsensusspecificitycontrast |
| 41.3% | offer | 5/7 | 2.5% | anchoringrisk-reversaleaseurgency |
| 42.1% | guarantee | 5/7 | 4.5% | risk-reversalreason-whyobjection-preemptcontrast |
| 56.6% | stakes | 2/7 | 1.1% | loss-aversionloop-closedfear-of-declinenew-mechanism |
| 59.7% | differentiation | 7/7 | 6.2% | contrastreason-whyspecificityborrowed-authority |
| 90.7% | close | 7/7 | 3.1% | loop-closedspecificityearned-authoritycommitment |
| 92.3% | product-reveal | 1/7 | 0.3% | loop-closed |
| 94.0% | future-pace | 1/7 | 1.9% | future-pacingeaserisk-reversal |